SEC Form 4 · accession 0001237899-19-000008
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher R. Fenimore
Officer — VP Controller
Period of report
Jan 18, 2019
Accepted (ET)
Jan 18, 2019 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 18, 2019 | M | 150 | $21.25 | A | 7,246 | D | |
| Common Stock | Jan 18, 2019 | G | 150 | $0.00 | D | 7,096 | D | |
| Common StockF1 | Jan 18, 2019 | G | 150 | $0.00 | A | 1,547 | I | By Trust |
| Common Stock | holding | — | — | — | 1,349 | I | By 401(k) Plan | |
| Common Stock | holding | — | — | — | 1,424 | I | by 2017 GRAT | |
| Common Stock | holding | — | — | — | 2,950 | I | by 2018 GRAT |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F2 | $21.25 | Jan 18, 2019 | M | 150 | D | — | Dec 18, 2019 | Common Stock | 150 | 350 | D |
Explanation of responses
- F1These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
- F2The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.